Effect of Renal Denervation on Catecholamines and the Renin-angiotensin-aldosterone System
Overview
Affiliations
Introduction: The effect of renal sympathetic denervation (RDN) on neurohormonal responses is largely unknown. We aimed to assess the effect of RDN on the renin-angiotensin-aldosterone system (RAAS) and endogenous catecholamines.
Methods: A total of 60 patients with hypertension underwent RDN and remained on a stable antihypertensive drug regimen. Samples for plasma aldosterone, plasma renin and urine (nor)metanephrine were collected at baseline and at 6 months post procedure. Ambulatory blood pressure (BP) recordings were obtained at baseline and at 6 months post procedure.
Results: Mean age was 64±9 years, and 30/60 patients were male. At 6 months, average daytime systolic and diastolic ambulatory BP decreased by 10 and 6 mmHg, respectively (<0.001). No significant change was observed in plasma aldosterone (median=248.0 pmol/L (interquartile range (IQR) 113.3-369.5 pmol/L) vs. median=233.0 pmol/L (IQR 110.3-360.8 pmol/L); =0.66); renin (median=19.5 µIU/mL (IQR 6.8-119.5 µIU/mL) vs. median=14.3 µIU/mL (IQR 7.2-58.0 µIU/mL); =0.32), urine metanephrine (median=0.46 µmol/L (IQR 0.24-0.77 µmol/L) vs. median=0.46 µmol/L (IQR 0.22-0.88 µmol/L); =0.75) and normetanephrine (median=1.41 µmol/L (IQR 0.93-2.00 µmol/L vs. median =1.56 (IQR 0.74-2.50 µmol/L); =0.58) between baseline and 6 months, respectively. No correlation was found between the decrease in mean systolic daytime BP and changes in RAAS hormones or endogenous catecholamines.
Conclusion: Despite significant reductions in ambulatory BP, RDN did not result in a significant change in endogenous catecholamines or in RAAS hormones at 6 months.
Renal denervation for hypertensive heart disease and atrial fibrillation.
Shinohara K Hypertens Res. 2024; 47(10):2665-2670.
PMID: 38877310 DOI: 10.1038/s41440-024-01755-y.
Yang X, Lin L, Zhang Z, Chen X J Clin Hypertens (Greenwich). 2022; 24(12):1537-1546.
PMID: 36321724 PMC: 9731592. DOI: 10.1111/jch.14590.
Catheter-based renal sympathetic nerve denervation on hypertension management outcomes.
Singh S, Varghese K, Qureshi F, Anderson M, Foxworth J, Knuepfer M World J Radiol. 2022; 14(7):238-248.
PMID: 36160631 PMC: 9350608. DOI: 10.4329/wjr.v14.i7.238.
Present Evidence of Determinants to Predict the Efficacy of Renal Denervation.
Zhou H, Xu Y, Chen W, Wang L, Du H, Liu H Int J Hypertens. 2022; 2022:5694127.
PMID: 35992203 PMC: 9391193. DOI: 10.1155/2022/5694127.
Li S, Hildreth C, Rahman A, Barton S, Wyse B, Lim C Sci Rep. 2021; 11(1):14286.
PMID: 34253766 PMC: 8275789. DOI: 10.1038/s41598-021-93575-0.